Omni Partners’s Verastem VSTM Stock Holding History

Omni Partners’s Portfolio VSTM Stock Details VSTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,571	Closed	-$205K	–	32
2017 Q4	$205K	Buy	+5,571	New	+$252K	0.04%	23

Other funds holding VSTM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Omni Partners's VSTM Position: Q1 2018 in Review

Omni Partners sold out of Verastem (VSTM) in Q1 2018, closing a stake of 5,571 shares — an estimated $205K sold.

Omni Partners first reported a position in VSTM in Q4 2017 and held it in 1 quarter. The position peaked at $205K in Q4 2017. 78 funds tracked by Wall St. Rank hold VSTM as of Q1 2018.

Omni Partners reported no remaining Verastem position as of Q1 2018 after selling out during the quarter.
Omni Partners sold 5,571 Verastem shares in Q1 2018, an estimated $205K.
Omni Partners first reported a position in Verastem in Q4 2017 and held it in 1 quarter.
Omni Partners's Verastem position peaked at $205K in Q4 2017.
78 funds tracked by Wall St. Rank held Verastem as of Q1 2018.

Based on Omni Partners's 13F filing for Q1 2018, filed 11 May 2018.